NPS Pharmaceuticals to Present at Jefferies Global Healthcare Conference
May 29 2013 - 4:10PM
Business Wire
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the
Jefferies 2013 Global Healthcare Conference in New York on Monday,
June 3, 2013 at 10:00 a.m. ET. The presentation will be available
as a live webcast with a replay available approximately three hours
after the presentation has concluded. Interested parties may access
the webcast from the investors’ calendar of events page on the NPS
website at http://www.npsp.com/calendar.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a global biopharmaceutical company
pioneering and delivering therapies that transform the lives of
patients with rare diseases worldwide. The company’s lead product,
Gattex® (U.S.)/Revestive® (EU) 0.05 mg/kg/d (teduglutide [rDNA
origin]) for injection is approved for adult short bowel syndrome
(SBS). NPS is also developing Natpara® (rhPTH[1-84]) for the
treatment of adult hypoparathyroidism and, subject to the
resolution of certain manufacturing issues, expects to submit its
Biologic License Application (BLA) to the FDA in 2013. NPS's
earlier stage pipeline includes two calcilytic compounds, NPSP790
and NPSP795, with potential application in rare disorders involving
increased calcium receptor activity, such as autosomal dominant
hypocalcemia with hypercalciuria (ADHH). NPS complements its
proprietary programs with a royalty-based portfolio of products and
product candidates that includes agreements with Amgen,
GlaxoSmithKline, Janssen Pharmaceuticals and Kyowa Hakko Kirin.
Nps (NASDAQ:NPSP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Nps (NASDAQ:NPSP)
Historical Stock Chart
From Oct 2023 to Oct 2024